Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($) Customer	Jun. 30, 2020 USD ($) Customer	Dec. 31, 2020 Customer
Summary Of Significant Accounting Policies [Line Items]
Amortization of acquired developed technology | $	$ 4,629	$ 1,907	$ 9,208	$ 3,693
Accounts Receivable
Summary Of Significant Accounting Policies [Line Items]
Number of customers			3		3
Product Revenues
Summary Of Significant Accounting Policies [Line Items]
Number of customers			3	3
Three Customers | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			100.00%		100.00%
Three Customers | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			100.00%	100.00%
Caremark LLC | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			35.00%		44.00%
Caremark LLC | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			37.00%	42.00%
PANTHERx Specialty Pharmacy LLC | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			35.00%		23.00%
PANTHERx Specialty Pharmacy LLC | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			35.00%	33.00%
Accredo Health Group, Inc | Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			30.00%		33.00%
Accredo Health Group, Inc | Product Revenues | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			28.00%	25.00%